EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)

Takehiro Kawashiri, Daisuke Kobayashi, Mayako Uchida, Shiori Hiromoto, Masashi Inoue, Hajime Ikeda, Mizuki Inoue, Takao Shimazoe

Journal of Pharmacy & Pharmaceutical Sciences · 11.10.2021 · 24 · 499-508

DOI: 10.18433/jpps31862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 11.10.2021. Verfasst von Takehiro Kawashiri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

As the prognosis of cancer patients deteriorates, secondary carcinogenesis after chemotherapy, especially secondary hematological malignancies, becomes a serious problem. However, information on the frequency and time of onset of secondary hematological malignancies and the risk of hematological malignancy with different drugs is scarce. This study aimed to evaluate the incidence of leukemia and myelodysplastic syndrome in patients with solid tumors, including breast, colon, gastric, pancreatic, small cell lung, non-small cell lung, esophageal, ovarian, cervical, and endometrial cancers.

Methods

Using the United States Food and Drug Administration Adverse Event Reporting System, we analyzed the reporting rates, reporting odds ratios, and the reporting onset times of secondary leukemia and myelodysplastic syndrome for each drug used.

Results

The leukemia reporting rates were higher in breast, small cell lung, ovarian, and endometrial cancers than in other cancers, and the myelodysplastic syndrome reporting rates were higher in ovarian and endometrial cancers than in other cancers. For each cancer type, the reporting odds ratios of cytocidal anticancer agents, such as taxanes, anthracyclines, alkylating agents, platinum, and topoisomerase inhibitors, were higher than those of other drugs. Alternatively, the reporting odds ratios of molecular targeted drugs and immune checkpoint inhibitors were not higher than those of other drugs. Approximately half of the cases of leukemia and myelodysplastic syndrome were reported within 1 to 4 years after chemotherapy.

Conclusions

Our study clarified the risks of leukemia and myelodysplastic syndrome for several anticancer drugs in patients with solid tumors. Our data may aid in the assessment of the risks of secondary leukemia and myelodysplastic syndrome when medical oncologists, clinical pharmacists, and patients select chemotherapy regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsAntineoplastic AgentsBreast NeoplasmsFemaleHumansLeukemiaLung NeoplasmsMyelodysplastic SyndromesNeoplasmsOvarian NeoplasmsSmall Cell Lung Carcinoma

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University.
  • Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Osaka, Japan.

Zitieren

APA

Kawashiri, T., Kobayashi, D., Uchida, M., Hiromoto, S., Inoue, M., Ikeda, H., Inoue, M., & Shimazoe, T. (2021). Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS). Journal of Pharmacy & Pharmaceutical Sciences, 24, 499-508. https://doi.org/10.18433/jpps31862

Vancouver

Kawashiri T, Kobayashi D, Uchida M, Hiromoto S, Inoue M, Ikeda H, et al. Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS). Journal of Pharmacy & Pharmaceutical Sciences. 2021;24:499-508. doi:10.18433/jpps31862

BibTeX
@article{Kawashiri2021,
  author = {Kawashiri, Takehiro and Kobayashi, Daisuke and Uchida, Mayako and Hiromoto, Shiori and Inoue, Masashi and Ikeda, Hajime and Inoue, Mizuki and Shimazoe, Takao},
  title = {Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2021},
  volume = {24},
  pages = {499--508},
  doi = {10.18433/jpps31862}
}
Kostenlos starten →